Can-Fite announces 1-for-3,000 reverse stock split effective January 2026

Can-Fite BioPharma Ltd. (NYSE American: CANF) announced its board approved a 1-for-3,000 reverse split of ordinary shares following shareholder approval on November 10, 2025.

The reverse split will be recorded with the Tel-Aviv Stock Exchange on January 2, 2026, with the first trading date for consolidated shares on January 5, 2026. Each 3,000 pre-split ordinary shares will automatically combine into one new ordinary share.

The company will simultaneously change its American Depositary Share ratio from one ADS representing 300 ordinary shares to one ADS representing two ordinary shares. The number of outstanding ADSs will remain unchanged. For ADS holders, this creates the equivalent of a one-for-twenty ADS split, requiring holders to exchange every 20 existing ADSs for one new ADS.

The Bank of New York Mellon will handle the ADS exchange process. The company's ADSs will continue trading on NYSE American under the symbol "CANF" with a new CUSIP number 13471N409.

The total number of outstanding ordinary shares will be reduced at a ratio of 3,000-for-one. The authorized number of ordinary shares will decrease from 42 billion to 14 million shares. Fractional ordinary shares will be rounded up to the nearest whole share per shareholder.

The reverse split will not affect shareholders' percentage ownership or voting power, except for minimal effects from fractional share treatment. Fractional ADS entitlements will be aggregated and sold by the depositary bank, with net proceeds distributed to applicable ADS holders.

Can-Fite stated the ADS price is expected to increase proportionally following the ratio change, though the company provided no assurance the post-change price will equal or exceed twenty times the pre-change price.

You May Also Be Interested In

• Apple suing OpenAI over alleged misappropriation of trade secrets
• Delta Air Lines (DAL) files mixed shelf
• Scribe Therapeutics Files for Nasdaq IPO